Try our Advanced Search for more refined results
Life Sciences - January, 2017
388 articles
- Gorsuch Likely To Restore Scalia-Era High Court Balance
- Gorsuch's Credentials Could Prove Troubling To Opposition
- Calif. Appeals Court Rebuffs Arbitration In Drug Co. Battle
- Bio-Rad GC Fired For Screw-Up And Temper, CFO Testifies
- 3 Gorsuch Opinions You Need To Read Right Now
- Teva Vows Appeal After 4 Copaxone Patents Invalidated
- Drug Buyer Hits Mylan, Sandoz, Taro With Price-Fixing Suit
- Trump Nominates Judge Gorsuch For High Court Seat
- Cancer Drug Co. Founder Accuses Brace Of Takeover Plot
- Da Vinci Robot Maker Escapes Suit Over Metal Debris
- FDA Warning Wire: A Winter Enforcement Storm
- Jurors To Hear Of Depakote Delay Link Despite FDA Block
- Biotech Twist Wants 'Opportunistic' Trade Secrets Suit Tossed
- UPS Can't Shake Frozen Embryo Mistreatment Case
- FDA's Streamlined Requirements For Combination Products
- Celgene Says 9th Circ. Ruling Means $40B FCA Suit Must Go
- Actavis, Lannett Hit With Antitrust Suit Over Gallstone Drug
- Indivior Must Face Suboxone Product-Hop Suit, States Say
- 10 False Claims Act Highlights Of 2016
- Some Early Trends In Post-Grant Review
- Prosecution Of Corporate Execs: The Latest Developments
- 2 Recent Decisions Provide Stock Promotion Guidelines
- Dems Boycott Vote On Trump's HHS, Treasury Noms
- FDA, Industry Face Hurdles With Trump Regulatory Overhaul
- First J&J Talc Cancer Trial In Calif. Set For July
- Mylan Facing Antitrust Probe Over EpiPen's Market Power
- Health Reg Rollback Will Hinge On Trump Order's Vagueness
- IP, Pharma Groups Call For Patent Eligibility Law Overhaul
- Small Pharmacies Seek Redo In Medco Antitrust Row
- In Loss For Merck, Amneal Gets OK For Generic Nasal Spray
- Diabetes Patients Fire Off First Suit Over Insulin Drug Hike
- Biotech Hit With Securities Class Action Over Sham Merger
- ARIAD Investor Slams $5.2B Takeda Deal For Unfair Process
- CORRECTED: Jury Awards Evonik $1.5M In Chem Bond IP Suit
- Nominee For HHS Sec Bought Discounted Biotech Stock
- 'Remarkable' E-Cig Liquid Law Partly Put Out By 7th Circ.
- Chicago Fights Latest Effort To Kill Opioid Addiction Suit
- Sperm Mixup Suit Put On Hold Amid State Court Case
- Love And Law In The Age Of Trump
- FTC Deceived Court On Pay-For-Delay Suit, Watson Says
- Sterne Kessler Adds 2 Kellogg Huber IP Pros As Directors
- An Update On Merger Filings In China
- Walgreens Boots Cuts Rite Aid Offer, Delays Closing
- FDA Memo Does Not Simplify 1st Amendment Considerations
- Trump Signs 'One In, Two Out' Order On Rulemaking
- The State Of The Litigation Finance Industry In 2017
- 9th Circ. Backs Millennium In $8.7M False Ad Coverage Suit
- Shire Prevails In Patent Trial Over Mylan's Generic Lialda
- Calif. Appeals Court Says Bone Doc Not Expert In Nexium Suit
- $61M Ends Sanofi Vaccine Antitrust Dispute
- Illumina Urges Fed. Circ. To Broaden Reach Of AIA Estoppel
- Hyland Homeopathic Teething Tablets Are Toxic, FDA Says
- Merck Pill Production Move Didn't Violate CBA, Judge Says
- Thompson & Knight Adds Litigation Partner From Reed Smith
- Taxation With Representation: Cravath, Vinson, Wachtell
- Merger Rules Shouldn't Stifle Drug Development: Vestager
- Patents Under The Trump Administration
- Health Hires: Lewis Brisbois, DLA Piper, Proskauer, Epstein
- 6 Firms To Steer IPOs Totaling $2.7B Led By Giant REIT
- 11th Circ. Ruling May Affect Criminal Securities Fraud Cases
- FDA Breaks Medical Product Communications Silence
- 'Complex' Acid-Reflux Drug Litigation Gives JPML Heartburn
- Cornerstone Investor Attys Get $4.9M In Merger Settlement
- Cynosure Agrees To Pay $16M To End Unwanted Fax TCPA Suit
- No Delay For Approaching Talc Trials, Mo. High Court Rules
- Ex-Accutane User's Time Limit Win May Draw Drug Suits To NJ
- Shkreli, Ex-Katten Atty Gear Up For Severance Fights
- Mylan, Sandoz, Taro Hiked Drug Price 1,000%, Union Says
- 5th Circ. Won't Consolidate Hip MDL Bellwether Appeals
- NY, La. Eyed For MDL Consolidation Of Blood-Thinner Suits
- Janssen Looks To Bar Sales Of Biosimilar In Remicade Suit
- 2 Life Sciences Cos. Price IPOs Totaling $172M
- Pump-Dump Fraudsters Pay SEC $9M, Firm Still Faces Suit
- Sorrento Directors Say Investor Suit Inadequately Pled
- Zimmer Gets Win In 3rd Knee Implant Bellwether
- Del. Justices Uphold Toss Of Salix-Valeant Merger Appeal
- Fed. Circ. Affirms Mylan Infringed Overdose Drug Patent
- Monsanto Fights To End Calif. Cities' PCBs Nuisance Row
- 4th Circ. Backs $3M Pelvic Mesh Verdict
- Cipro Buyers, Barr Reach $225M Deal In Pay-For-Delay Suit
- Medtronic Gets $20.3M Infringement Verdict Cut By $2.6M
- GSK Says No Basis For Fraud Claims In Zofran MDL
- Feds Tell High Court To Pass On Flanax Trademark Case
- PTAB Expertise Key Factor To Landing AIA Work, GCs Say
- Temasek Invests $800M In Alphabet's Verily Life Sciences
- 6 Ways To Get More From A Limited Budget For Trial Graphics
- Lannett, Mylan Fixed Thyroid Drug Price, Suit Says
- 4 PTAB Lessons On Scope Of On-Sale Prior Art
- J&J Grabs Swiss Rare Drug Co. Actelion In $30B Cash Deal
- EU Antitrust Watchdog Unsure About Merger Alert Reforms
- Dialysis Cos. Win Freeze Of HHS Premium Assistance Rule
- Bio-Rad GC's Corruption Report Baseless, Atty Testifies
- Deals Rumor Mill: Siemens, SK Capital Partners, Kate Spade
- Doctors Urge Fed. Circ. To Keep Cholesterol Drug On Market
- Del. Justices Seek Details In $13B Salix Merger Appeal
- Top Health Cos. Press Trump On Value-Based Care
- Hooper Lundy Adds DOJ Health Fraud Deputy In Boston
- Judge Excluded Zoloft MDL Expert Too Soon, 3rd Circ. Told
- Perrigo Seeks New Trial After $10M Patent Verdict
- Pfizer Returns Fire In Advil-Tylenol Advertising Suit
- At PTAB, Mylan Blasts AstraZeneca Over $3.5B Diabetes Meds
- EU Conditionally Approves Abbott's $5.8B Purchase Of Alere
- Carefully Tailored ERISA Claims After Amgen V. Harris
- Bio-Rad Ex-GC Asks For $8M On Contentious Trial Day
- FDA Warning Wire: Zimmer Rapped In Inspection, Again
- Pharma Refund Co. Can't Nix Evidence Of Money Laundering
- Apotex Slams Merck's Nasonex Generic Suit As Redundant
- Glaxo Looks To Bar FDA, Plea Evidence From Paxil Trial
- Valeant Says Zydus' Cardizem Generic Infringes Patent
- NJ Justices Apply That State's Time Limit To $25M Drug Suit
- A Return To Republican Antitrust Policies For Pharma
- Taxing Marijuana: A Hazy Issue For Municipal Bankruptcy
- Purdue Sued By Wash. City Over Costs Of Opioid Crisis
- Judge Allows Ariosa Invalidity Arguments From AIA Petition
- Endo Settles Pay-For-Delay Suit As FTC Renews Watson Case
- Mallinckrodt Hit With Securities Suit After $100M FTC Deal
- Bio-Rad CEO Tells Jury Ex-GC 'Came Unglued' After DOJ Fee
- Medtronic, IRS Agree On $14M Tax Bill In Transfer Pricing Row
- IRS Wants Mylan To Give Up Docs Over $400M IP Deal
- GSK Seeks Win In Denture Cream Health Effects MDL
- KaloBios Investors Take $1.5M Deal But Still Target Shkreli
- 10 Antitrust Trends And Developments To Watch This Year
- WTO Loosens Drug Patent Rules For Poorer Nations
- Hospital Wants To Triple $10M Jury Verdict Over Pepcid Patent
- Kaneka Health Supplement Patent Suit Revived By Fed. Circ.
- Deals Rumor Mill: Blackstone, Jose Cuervo, Cynosure
- Former DC Prosecutor Returns To DLA Piper
- Zimmer Wants Claims Limited In Knee Implant Trial
- Consumers Fight Alere Dismissal Bid In Blood Test Suit
- Pfizer Hits Back At Texas In Rebate Info Disclosures Suit
- Bayer Suit Over False Mirena Price Listing Survives
- Calif. Judge Trims Supplement Buyer's False Ad Suit
- Everything To Know About EPA's Final Nanoscale Rule
- Merck Pays Bristol-Myers $625M In Cancer Treatment IP Row
- Obama's FDA Leaves Mark With Last-Minute Policy Blitz
- 8 Firms To Steer IPOs Totaling $1.9B As 2017 Gets Cranking
- Head Of Meningitis-Linked Pharmacy Called Regulators Inept
- Anthem Agrees To Lift Extra Step In Opioid Rehab Coverage
- Agile Lied About Birth Control Patch Study, Investor Says
- Taxation With Representation: Cravath, Weil, Jones Day, Davis
- Sanction Bid in Dismissed IP Case Still Valid, Sloan Says
- Herbalife In SEC Hot Seat Over China Anti-Corruption Stance
- Bayer MDL Firm Fights 'Frivolous' Sanctions In Fee Dispute
- How Litigation Funding Is Bringing Champerty Back To Life
- Lessons From The Largest Patent Damages Award In History
- Bio-Rad CEO Tells Jury He Backdated Fired Exec's Review
- DNA Testing Customer Says Privacy Row Ideal For Class Cert.
- Alleged Ringleader Pleads Guilty In $175M Health Fraud
- Fla. AG Files Water Chemical Antitrust Suit In NJ
- Rolling Back Regulation In The Age Of Trump
- In The Polarized Era Of Trump, BigLaw Searches For Balance
- The Lawyer Who Will Shape Trump's Presidency
- Most Influential Judges On Trump's Supreme Court Short List
- Monsanto Can't Keep Ex-Atty Out Of Syngenta MDL
- AbbVie Fires Back At Investors' Suit Over Failed Merger
- Walgreens To Pay $50M To Settle Feds' Kickback Claims
- Ethicon Trims Failure To Warn Claims In Mesh MDL
- BioScrip Investors Try To Save Suit After Targeting New Board
- PTAB Invalidates RainDance Diagnostic Testing Patent
- Costco To Pay $11.75M Over Lax Pharmacy Oversight
- Judge Axes Roche TB Test Patent As Natural Phenomena
- Small Pharmacies Lose Class Cert. In Caremark Antitrust Row
- High Court To Hear Dispute Over Plavix Users' Calif. Ties
- Attracting And Retaining The Millennial Lawyer
- Devos Wants Evidence Barred In Money Laundering Case
- Hip Implant Plaintiff Shows Early Bird May Not Get The Worm
- Colgate Seeks To Brush Away Toothpaste False-Ad Suit
- Health Care Enforcement Review And 2017 Outlook: Part 4
- Niro Attys Again Face Sanctions In Sloan-Kettering IP Row
- Fraud Conviction Stands, But Atty Wins $13M Penalty Review
- Bio-Rad's Ex-GC Testifies CEO Resisted FCPA Investigation
- Widow Tells Jury Of Husband's Death From Tainted Steroids
- 5 Key Exchanges At HHS Nominee's Grilling
- $5M Deal On J&J Bedtime Baby Products OK'd
- Merck Says K-Dur Buyers Can't Save Pay-For-Delay Suit
- FDA Allows More Input On Off-Label Drug Promotion Limits
- Med Device Co. Pays $14M Over Accounting, FCPA Violations
- Private Education Giant, Biotech Launch IPOs Totaling $687M
- Asset Swap Transactions In The Antitrust Crosshairs
- New Claim Of Death Emerges In Xarelto MDL
- $21M Interest Added To CardiAQ Trade Secrets Win
- Mallinckrodt Inks $100M Antitrust Deal With FTC, States
- Pentax Medical Devices Carry Infection Risk, FDA Says
- It's Time To Change The Law Firm Business Model
- Eli Lilly Pays $960M For Migraine Treatment Developer
- Health Care Enforcement Review And 2017 Outlook: Part 3
- 2 Ways Courts Approach Willful Infringement After Halo
- FDA Adverse Event Data Release May Mean More Lawsuits
- Bio-Rad Fired GC For FCPA Leak, Jury Told At Trial's Start
- McKesson Gets $150M DOJ Fine For Ignoring Sketchy Orders
- Stem Cell Group Denies Selling Fraudulent Treatments
- 3 Takeaways As FDA Dishes On Interchangeable Biosimilars
- After Historic Vote, Fla. Drafts New Medical Pot Rules
- Stryker Accused Of Firing Specialist For Refusing Surgeries
- Drug Cos. Aim To Force Market Discovery In Loestrin MDL
- Allergan Pays $15M For Failing To Disclose Merger Talks
- Biogen To Pay $1.25B For Forward Pharma's MS Drug IP
- 7 Companies Launch IPOs Totaling $1.7B As 2017 Heats Up
- FDA's Foreign Offices Are Short-Staffed, Report Says
- Law360's Pay-For-Delay Cheat Sheet For 2017
- Jury Told Zimmer Skimped On Warnings For Obese Patients
- Justices Decline J&J Patent Appeal Over Expert Misconduct
- Key Trade Secret Developments Of 2016: Part 2
- Defibrillator Decision Does Not Shock The Conscience
- Amended Rule 37(e): 1 Year Later
- Health Care Enforcement Review And 2017 Outlook: Part 2
- Evidence Substantiation Burden May Soon Shift To FTC
- Dechert's New Hong Kong Team Seals 5 Deals In First 2 Weeks
- Bayer Gets Freebie As Atty Neglect Sinks Yasmin Suit
- FDA Issues Guidance On How It OKs Device Tests In Humans
- Spouse Of FTC Witness In Diet Pill Suit Avoids Sanctions
- Pharmacy That Sold Deadly Drugs Touted Safety, Jury Told
- J&J Seeks OK Of $5M Baby-Product False Ad Settlement
- Deal Makers Buoyed After JPMorgan Forum Despite Clouds
- Agilent Rival Can't Trim Trade Secret Suit Over DNA Tech
- Actavis, Sandoz Rigged Anesthetic Cream Prices, Union Says
- Artificial Heart Maker Gets Ch. 11 Dismissal Approved
- Health Hires: 7 New Life Sciences, Health Additions
- Avoiding The Hidden Costs Of Bargain-Priced E-Discovery
- Taxation With Representation: Baker, Cleary, Paul, Kirkland
- Dabbing Into The Financial Side Of Marijuana
- Dance Marches On For Biosimilars In Amgen V. Sandoz
- Actavis, Sandoz Hit With Antitrust Suit Over Skin Drug
- High Court Takes Up Amgen-Sandoz Biosimilar Brawl
- KKR Inks $1.3B Deal For Hitachi Power Tool Unit
- FDA Floats New Oversight Plan On Lab Tests
- Health Care Enforcement Review And 2017 Outlook: Part 1
- DaVita, Fresenius Win Temporary Block Of HHS Rule Change
- Judge Won't Set 1st Calif. J&J Talc Cancer Trial Date Yet
- Atty Misconduct Not 'Egregious,' Judge Finds In Bayer Suit
- Zimmer Biomet To Pay $30M For Breaching FCPA Deal
- Sens. Reintroduce Bill Regulating Pay-For-Delay Deals
- Del. Theranos Suit Docs OK'd For Use In Other Actions
- Baxter To Pay $18M Over IV Fluid-Making Conditions
- Judge Knocks Out Imaging Patent For Inequitable Conduct
- Fed. Circ. Backs Eli Lilly Alimta Patent Win Under Akamai
- Agencies At Fault In Meningitis MDL Too, Surgery Center Says
- United Healthcare, Class Refute AGs' Protest To Hep C Deal
- Deals Rumor Mill: Johnson & Johnson, Onex, McDonald's
- A Record FCPA Year For Pharma
- Qiagen Asks Fed. Circ. To Lift DNA Sequencer Ban
- Trump's HHS Choice Inks Ethics Deal With Gov't Watchdog
- MIT Seeks $8M Fee Award In Gene Silencing Patent Fight
- Horizon Hits NJ Mail Order Pharmacy With $10M Suit
- The Outlook For The Pharmaceutical Industry Under Trump
- The Serious And Immense Impact Of A Medical Device Hack
- Saving Lawyers 1 Breath At A Time: Mindfulness In The Law
- FDA Sticks With Suffixes On Biosimilar Names
- Novo Nordisk Accused Of Fixing Prices To Hide Sales Slump
- Insurer Tells 9th Circ. Millennium Lab Suits Aren't Covered
- Shire Accused Of Cutting Pay-For-Delay Deal On ADHD Drug
- Greenberg Denies Fla. Biotech's $1B Malpractice Claims
- 7 Key Policies In HHS Inspector General's Exclusion Rule
- Theranos Seeks Out Of Blood-Testing Suits
- Meningitis-Linked Pharmacy Used Fake Names, Jury Told
- Feds Urge Against Rule Injunction In Dialysis Program Suit
- Alere Says Home Blood Test Class Action Is Full Of Holes
- ERISA Blocks Iowa Pharmacy Benefits Law, 8th Circ. Says
- Sanofi Accused Of Blocking Rival On Diabetes Drug
- Drug Return Co. Loses Bid To Trim $116M Diversion Case
- Latham & Watkins Steers Integra's $204M Derma Sciences Buy
- Surgeon Group Can't Nix LA's Spinal Implant Overcharge Row
- Consumer Orgs Ask 1st Circ. To Ax Momenta Antitrust Shield
- Czechia Says Several Courts Agree $328M Award Is Void
- Biotech Co. Hid Cancer Drug Concerns, Investors Say
- Children's Advil Ad Ban Is Proper, J&J Unit Tells 2nd. Circ.
- What To Expect From China's Anti-Monopoly Law This Year
- Understanding How Blockchain Could Impact Legal Industry
- Why The Learned Intermediary Doctrine Should Survive
- Harwood Lloyd Seeks $819K From Ex-Client In Generics Case
- Amgen Beats Decade-Old Investor Suit Over Off-Label Scheme
- Gilead Calls $50M Cancer Drug Bonus Demand 'Absurdity'
- FDA Reports Hacking Risk In St. Jude Medical Heart Devices
- Sanofi Can't Ditch Ex-Worker's FCA Claims Over Cancer Drug
- Deals Rumor Mill: Brookdale, Imagina Media, Carlyle Group
- 9th Circ. Won't Rehear Investor Suit Over Arena's Diet Drug
- Pharmacist Denied Problems Amid Meningitis Probe, Jury Told
- 1st Circ. Won't Rethink Nexium Pay-For-Delay Decision
- FDA OKs Abuse-Deterrent Opioid, Minus Some Label Claims
- Suits Over Defective Wright Hip Implant Stems Combined
- Whole Foods Hit With Class Action Over Supplement Claims
- Ex-NJ Pharma Execs Admit To Generic Drug Price-Fixing Plot
- McCain, Klobuchar Take 3rd Shot At Drug Import Bill
- Valeant Unloads $2B In Assets To Pay Down Debt
- Apparent Settlement Authority In A Paragraph IV Dispute
- Amgen Argues Decade-Old Derivative Suit Still Lacks Facts
- Mich. Spinal Surgeon Gets 20 Years For $2.8M Fraud Scheme
- 1st Circ. Won't Revive Spinal Therapy Co. Investor Suit
- The Firms That Dominated In 2016
- Drug Wholesalers To Pay $36M Over W.Va. Pill Mill Claims
- Supreme Court Rejects Merck Bid To Eye On-Sale Bar's Reach
- Omitted Testimony Affected Fee Fight, Firm Tells 11th Circ.
- Justices Won't Review PTAB's Power To Start AIA Reviews
- 5th Circ. Asked To Consolidate Hip MDL Bellwether Appeals
- Sanofi Vows Appeal After Drug Injunction Stay Is Denied
- Griffin Capital REIT Nabs NJ Office Building In $44M Deal
- Fed. Circ. Finds PTAB Wrongly Rejected Scalpel Patent Claim
- Meningitis Outbreak Was Murder, Feds Tell Jury
- Law360 Names Practice Groups Of The Year
- Ex-AdvoCare Director Must Arbitrate Claim Over CEO Job
- Takeda Inks $5.2B Deal For Oncology-Focused ARIAD
- Abbott, Alere Offer EU Antitrust Fixes For $5.8B Deal
- Popular Memory Booster Lacks Proof Of Benefits, FTC Says
- Fed. Circ. Finds No Standing For Appeal Of PTAB Drug Ruling
- SEC Judge Says PwC Auditor Must Face Fund Fraud Suit
- Atrium Medical Accused Of Hiding Surgical Mesh Risks
- $337M Has GSK Research Complex Trading Hands
- Top 5 Drug And Device Developments Of 2016
- Supreme Court Won't Hear ANDA Venue Case
- Investors Target Contraception Maker Over Stock Drop
- Merrimack Agrees To Sell Ipsen Cancer Drugs In $1.03B Deal
- FCPA Predictions For 2017
- Easing The Process For Requesting Experimental Drugs
- DOJ Subpoenas DaVita, Fresenius Over Dialysis Aid Program
- 3 Questions Shaping 2017 JPMorgan Health Care Conference
- Take Slashed Verdict Or Face New Med Mal Trial, Family Told
- Bankrupt Lensar Seeks Quick Access To Lender Cash
- Kyorin To Settle Apotex Pinkeye Meds Product-Hopping Suit
- Drug Wholesaler Cops To $100M Prescription Meds Fraud
- J&J Settles Latest Risperdal Case Before Trial
- The Biosimilars Litigation Landscape For 2017
- Giving Pfizer Rebate Info To Lawmakers Legal, Texas Says
- Illumina-Backed Cancer Screening Co. To Raise Over $1B
- Taxation With Representation: Bracewell, Gibson, Baker
- Mylan Sues IRS For Nixing $42M In Patent Litigation Write-Offs
- 5 FCA Issues To Watch As Trump Takes Power
- Real Estate Rumors: Pfizer, Heafey, Banco Bradesco
- Generic Drug Price-Fixing Suits Just Tip Of The Iceberg
- Pa. Judge Won't Ax $13.7M Pelvic Mesh Award
- KKR Injects $60M In Slayback Pharma
- The Duty To Supplement Expert Reports: Part 2
- 5 Insights From General Electric's Alex Dimitrief
- Amgen Wins Injunction On Sale Of Sanofi's Cholesterol Drug
- Alston & Bird DQ'd From CytImmune Noncompete Dispute
- NJ Appeals Judge And Mass Tort Jurist Carol Higbee Dies
- Staar Surgical Investors Snag Class Cert. In Stock-Drop Suit
- Lifewatch Must Turn Over Docs In Robocall Suit, FTC Says
- Genentech Presses For Cancer Drug Patent's Invalidation
- UK Competition Watchdog Taps 3 For Senior Roles
- Fenwick Guides Cancer Biotech Loxo's $120M Follow-On
- Ex-Insys Execs Plead Not Guilty To Pain Pill Kickback Con
- Mylan, Teva, Others Face Blood Pressure Drug Antitrust Suit
- Warner Chilcott Denied Sales Docs In Asacol Antitrust Suit
- J&J Denied Delay Request In Talc Cancer Missouri Trials
- Insomnia Device Maker Cerêve Raises $38M From KKR, Others
- The Path Forward For Industrial Hemp In Indian Country
- Houston Firm Wants High Court Review Of Fen-Phen Fee Row
- GE Urges Nix Of DQ 'Retaliation' In Incubator Patent Row
- The Duty To Supplement Expert Reports: Part 1
- Finding Conflict, Chief Justice Leaves Patent-Export Case
- Teva Ducks Whistleblower's Off-Label Marketing FCA Suit
- Judge Won't Toss Expert In Zimmer Trial, But Trims Claims
- Actavis, Mylan, Teva Rigged Cholesterol Drug Price, Suit Says
- South Korean Capital Markets Volume Hits 6-Year High
- Amneal Sees Key Suboxone Product-Hopping Claims Advance
- Wholesaler To Pay WV $3.5M Over Suspicious Drug Orders
- J&J Says Pfizer Unit Jointly Liable In Remicade Patent Suit
- PTAB Rejects MRI Patent Claims As Abstract Under Alice
- Investors Target Allergan After DOJ Price-Fixing Probe
- Families Hit Back At GSK'S Zofran Fraud Dismissal Bid
- Legal Loopholes For Dietary Supplements Must Be Sealed
- J&J Gets $1B Damages Cut In Half In Hip Verdict
- GSK Vaccine Sales Exempt From Antitrust Law, 9th Circ. Says
- Dental Instrument Patent Claims Found Invalid In PGR
- AbbVie Can't Trim Report In Testosterone Replacement MDL
- GOP Rep. Goodlatte Proposes Repeal Of Chevron Doctrine
- Texas Sues FDA Over Death Penalty Drug Import Delay
- Jury Verdict Upheld In Amgen Cholesterol Drug Patent Row
- Fed. Circ. Affirms PTAB Nix Of J&J Unit's Stent Patent
- 11th Circ. Nixes Procaps' Bid To Revive $255M Antitrust Suit
- Be Prepared For Law Firm Data Breach Litigation
- FDA Warning Wire: Enforcement Surge Targets Pharma Promos
- Trader Drops 3rd Circ. Appeal Of SEC Insider Trading Deal
- 'Unicorn' AppDynamics Leads 5 IPOs Filed In Year-End Blitz
- Medtronic Investors Get Shady-Study Suit Redo In 8th Circ.
- How A False Claims Act Case Works — Or Fails
- La. Bound To Flonase Settlement, GSK Tells 3rd Circ.
- Versant Ventures Nabs $400M For Biotech Investment Fund
- Boehringer, Sanofi Close Deal As FTC Orders Divestitures
- 1st Circ. Won't Revive FCA Suit Against Medtronic Unit
- Abbott To Wrap Up $25B St. Jude Buy With FTC's Approval
- Braeburn Pharmaceuticals Files For $150M IPO
- FTC Wants Endo's Challenge To Its Litigation Power Nixed
- 7 Legal Industry Predictions For 2017
- Life Sciences Cases To Watch In 2017
- Life Sciences Legislation And Regulation To Watch In 2017
- Product Liability Cases To Watch In 2017
- New Jersey Cases To Watch In 2017